Eric Venker serves as Chief Executive Officer of Immunovant Inc., where he leads the company's strategic direction in developing targeted therapies for autoimmune diseases. With a background in biotechnology and pharmaceutical operations, Venker previously held senior roles at Roivant Sciences, focusing on portfolio management and clinical advancement of novel drug candidates. His work has emphasized efficient drug development processes and building collaborative networks across the industry. Throughout his career, Venker has contributed to the progression of multiple immunology programs from early-stage research to late-phase clinical trials, achieving key milestones such as regulatory designations and expanded indications for investigational treatments. He has also played a part in securing substantial capital investments to support pipeline growth and operational scaling at Immunovant. As CEO, Venker oversees research, development, and commercialization efforts, guiding the organization toward potential approvals for therapies like batoclimab while fostering a culture of innovation and patient-centric focus. His leadership has positioned the company to address significant unmet needs in conditions such as myasthenia gravis and thyroid eye disease.